摘要
乳腺癌相关淋巴水肿(breast cancer related lymphedema,BCRL)是乳腺癌综合治疗后的常见并发症,主要表现为患侧上肢肿胀和皮肤改变,显著影响患者的肢体功能和生活质量。BCRL受手术、放疗、药物、感染、创伤等多种因素影响,因而明确潜在危险因素对于采取个体化预防策略至关重要。基于循证证据的BCRL风险评估模型可以帮助临床医生评估和识别高风险患者,应用前瞻性监测手段为早期干预BCRL创造机会;而对于BCRL晚期的患者则可通过保守治疗和手术治疗等方式控制及改善症状。本文对BCRL的风险因素、评估监测手段、治疗策略及相关研究进展进行了全面综述,为此领域的多学科协作和临床诊疗提供参考。
Breast cancer-related lymphedema(BCRL)is one of the most common complications after multidiscipline treatment of breast cancer,which manifests as upper limb swelling and skin changes and significantly affects limb function and quality of life.The occurrence and development of BCRL are affected by many factors including surgery,radiotherapy,drugs,infection,trauma,and so on.Therefore,it is important to identify the potential risk factors to establish individualized prevention strategies.Evidence-based risk assessment models for BCRL could help clinicians to identify high-risk patients and apply prospective surveillance to treat BCRL at early stage.For patients with advanced lymphedema,conservative treatment and surgical treatment could be delivered to relieve symptoms and improve their conditions.This article comprehensively reviewed the risk factors,prospective surveillance,intervention,and research progress of BCRL,to provide reference for multidisciplinary collaboration as well as clinical diagnosis and treatment in this field.
作者
黄佳淇
郑思悦
朱琪伟
曹璐
陈佳艺
HUANG Jiaqi;ZHENG Siyue;ZHU Qiwei;CAO Lu;CHEN Jiayi(Department of Radiation Oncology,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China;Shanghai Key Laboratory of Proton-therapy,Shanghai 201801,China;Department of Radiation Oncology,Affliated Tumor Hospital of Nantong University,Nantong 226361,Jiangsu Province,China)
出处
《肿瘤》
CAS
北大核心
2023年第9期747-755,共9页
Tumor
基金
上海市2023年度“科技创新行动计划”医学创新研究专项项目(23Y41900100)
国家重点研发计划(2022YFC2404602)
市级医院诊疗技术推广及优化管理项目资助(SHDC12023108)
2022年度上海市科学技术委员会“科技创新行动计划”医学创新研究专项独立子课题(22Y31900103)
上海市卫生健康委员会卫生行业临床研究专项(20224Y0025)
北京科创医学发展基金会项目(KC2021-JX-0170-9)
国家自然科学基金资助(82373514,82373202)
